title: [Study on pharmacokinetics of 20 (S) -protopanaxadiol lipid cubic nanoparticles].
abstract: OBJECTIVE
  To establish a high-performance liquid chromatographic/tandem mass spectrometry (HPLC-MS/MS) method for determining 20(S)-protopanaxadiol (PPD) in rat plasma, in order to analyze pharmacokinetic characteristics of PPD and PPD cubic nanoparticles.
  
  
  METHODS
  Sprague-Dawley rats were administered orally with PPD and PPD cubic nanoparticles, respectively. Their blood samples were obtained from fossa orbitalis at regular time points. The mobile phase was 0.05% formic acidac etonitrile-0.05% formic acidac water (95:5). Electrospray ionization (ESI) was adopted for the quadrupole tandem mass spectrum. SCAN mode was used for the quantitative analysis, with m/z 460. 4/425.3 and m/z 622.9/318.3 (Rh2, interior label) as secondary fragment ions. The concentration of PPD in plasma was analyzed. The concentration-time curve was mapped. The data were calculated by DAS program.
  
  
  RESULTS
  The linearity of the PPD plasma concentration determination method ranged between 10-1 407 microg x L(-1), with the limit of quantification of 2.5 microg x L(-1). Both of the inter-day and intra-day precisions (RSD) were less than 13.25%, and the accuracy (relative error) was between +/- 8.50%.
  
  
  CONCLUSIONS
  The method was so highly specific and sensitive with less plasma that it is suitable for pharmacokinetic studies. The prepared 20(S)-protopanaxadiol lipid cubic nanoparticles can enhance its absorption in vivo. Its relative bioavailability is 166% of the raw material.
authors.affiliation: Hospital of Chinese and Western Integrated Medicine affiliated, Nanjing University of Chinese Medicine, Nanjing 210028, China. jinxin871211@163.com
authors.forename: Xin
authors.initials: X
authors.lastname: Jin
authors.forename: Zhen-Hai
authors.initials: ZH
authors.lastname: Zhang
authors.forename: E
authors.initials: E
authors.lastname: Sun
authors.forename: Qi-Yuan
authors.initials: QY
authors.lastname: Liu
authors.forename: Xiao-Bin
authors.initials: XB
authors.lastname: Jia
mesh_terms: D000042:Absorption; D000284:Administration, Oral; D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D005260:Female; D008055:Lipids / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D053758:Nanoparticles; D051381:Rats; D017207:Rats, Sprague-Dawley; D012502:Sapogenins / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D012680:Sensitivity and Specificity; D021241:Spectrometry, Mass, Electrospray Ionization; D053719:Tandem Mass Spectrometry / Q000379:methods; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D008055:Lipids; D012502:Sapogenins; C062916:protopanaxadiol